Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026

REHOVOT, Israel and HOBOKEN, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

GlobeNewsWire • Oct 19, 2026

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Million in Annual Revenue by 2030 Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Million in Annual Revenue by 2030

GlobeNewsWire • Oct 6, 2026

Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth

Kamada NASDAQ: KMDA outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to expand through product sales, distribution agreements, plasma supply and potential acquisitions.

MarketBeat • Sep 27, 2026

CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand

U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two FDA-Approved Anti-Rabies Immunoglobulin Products in the U.S. Market Estimated at $200 Million Annually Kamada's Manufacturing Capacity and Supply Availability Positioned to Support Increased Demand REHOVOT, Israel, and HOBOKEN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

GlobeNewsWire • Sep 17, 2026

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel.

GlobeNewsWire • Sep 10, 2026

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders

REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA”) with respect to the cash dividend of $0.17 (approximately NIS 0.51) per share on the Company's ordinary shares (totaling approximately $9.8 million) announced on August 17, 2026 (the “Dividend”), expected to be paid on September 17, 2026 (the “Payment Date”), to shareholders of record at the close of business on August 27, 2026 (the “Record Date”).

GlobeNewsWire • Sep 3, 2026

AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be The Cure

For investors seeking opportunities outside the AI trade, healthcare stocks can offer diversification without sacrificing exposure to growth. S&P 500 healthcare earnings are projected to rise by 22% YoY in 2027, the second-highest estimated growth rate among the eleven sectors, topped only by technology. According to JPMorgan analysts, at a time when many investors remain highly concentrated in the AI theme, healthcare offers a rare combo of durable growth, tech-like margins, and value.

Seeking Alpha • Sep 1, 2026

Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026

Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consistent with the Company's Cash Dividend Policy

GlobeNewsWire • Aug 17, 2026

Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet

The consensus price target hints at a 79.1% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Aug 14, 2026

Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research • Aug 14, 2026